Singapur - angielski - HSA (Health Sciences Authority)

pfizer private limited - palbociclib - tablet, film coated - palbociclib 100 mg

Singapur - angielski - HSA (Health Sciences Authority)

pfizer private limited - palbociclib - tablet, film coated - palbociclib 125 mg

Singapur - angielski - HSA (Health Sciences Authority)

pfizer private limited - palbociclib - tablet, film coated - palbociclib 75 mg

Malezja - angielski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - palbociclib -

Malezja - angielski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - palbociclib -

Malezja - angielski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - palbociclib -

Malezja - angielski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

duopharma hapi sdn. bhd. - palbociclib -

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - palbociclib 100mg - film coated tablet - 100 mg - active: palbociclib 100mg excipient: colloidal silicon dioxide crospovidone opadry green 03k110010 magnesium stearate microcrystalline cellulose succinic acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - palbociclib 125mg - film coated tablet - 125 mg - active: palbociclib 125mg excipient: colloidal silicon dioxide crospovidone opadry purple 03k100008 magnesium stearate microcrystalline cellulose succinic acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - palbociclib 75mg - film coated tablet - 75 mg - active: palbociclib 75mg excipient: colloidal silicon dioxide crospovidone opadry purple 03k100008 magnesium stearate microcrystalline cellulose succinic acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.